A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

Journal: Nature Biotechnology

Published: 2020-07-23

DOI: 10.1038/s41587-020-0631-z

Affiliations: 14

Authors: 16

Go to article
Institutions Share
Duke-NUS Emerging Infectious Diseases (EID), Singapore 0.44
Genscript Biotech Corporation, China 0.13
Second Hospital of Nanjing, NJUCM, China 0.09
SingHealth Duke-NUS Global Health Institute (SDGHI), Singapore 0.06
National Centre for Infectious Diseases (NCID), Singapore 0.06
NUS Saw Swee Hock School of Public Health (SSHPH), Singapore 0.03
Center for Global Health, NJMU, China 0.03
Duke-NUS Graduate Medical School Singapore, Singapore 0.03
Tan Tock Seng Hospital (TTSH), Singapore 0.03
Lee Kong Chian School of Medicine, Singapore 0.03
NUS Department of Microbiology and Immunology (MBIO), Singapore 0.02
National University Health System (NUHS), Singapore 0.02
Institute of Molecular and Cell Biology (IMCB), A*STAR, Singapore 0.02
NUS Yong Loo Lin School of Medicine (YLLSoM), Singapore 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER